InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research note issued on Sunday. The brokerage set a "sell" rating on the stock.

A number of other research firms also recently commented on NSPR. Piper Sandler reaffirmed an "overweight" rating and set a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital initiated coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a "buy" rating and a $5.00 target price for the company.

InspireMD Stock Performance

NYSE NSPR traded up $0.05 during mid-day trading on Friday, reaching $2.71. 12,071 shares of the stock were exchanged, compared to its average volume of 57,785. The stock has a market capitalization of $70.69 million, a PE ratio of -3.61 and a beta of 0.99. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42. The business's fifty day simple moving average is $2.74 and its 200 day simple moving average is $2.70.

InspireMD (NYSE:NSPR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. The business had revenue of $1.81 million for the quarter, compared to analysts' expectations of $1.74 million. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. During the same quarter last year, the firm earned ($0.15) earnings per share. On average, analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new stake in InspireMD, Inc. (NYSE:NSPR - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 104,081 shares of the company's stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned 0.42% of InspireMD at the end of the most recent quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.